{"id":"ipilimumab-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Immune-related endocrinopathy"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ipilimumab is a monoclonal antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a negative regulator of T-cell activation. By blocking CTLA-4, the drug removes a 'brake' on the immune system, allowing T cells to become more activated and proliferate, thereby enhancing their ability to recognize and attack cancer cells. This mechanism of immune checkpoint inhibition has demonstrated clinical benefit in melanoma and other malignancies.","oneSentence":"Ipilimumab blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:02.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Advanced melanoma"}]},"trialDetails":[{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT03070392","phase":"PHASE2","title":"Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma","status":"COMPLETED","sponsor":"Immunocore Ltd","startDate":"2017-10-16","conditions":"Uveal Melanoma","enrollment":378},{"nctId":"NCT06708949","phase":"PHASE2","title":"A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-03-20","conditions":"Renal Cell Carcinoma, Clear Cell","enrollment":15},{"nctId":"NCT05176483","phase":"PHASE1","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","status":"RECRUITING","sponsor":"Exelixis","startDate":"2021-12-14","conditions":"Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC)","enrollment":1314},{"nctId":"NCT07000149","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-28","conditions":"Advanced Clear Cell Renal Cell Carcinoma","enrollment":1116},{"nctId":"NCT03223155","phase":"PHASE1","title":"Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2017-09-07","conditions":"Stage IV Small Cell Lung Cancer","enrollment":78},{"nctId":"NCT06097728","phase":"PHASE3","title":"MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-09","conditions":"Unresectable Pleural Mesothelioma","enrollment":825},{"nctId":"NCT05536141","phase":"PHASE1","title":"A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors","status":"RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2022-10-26","conditions":"Clear Cell Renal Cell Carcinoma, Solid Tumors","enrollment":362},{"nctId":"NCT04290546","phase":"PHASE1","title":"CIML NK Cell in Head & Neck Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-07-20","conditions":"Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":11},{"nctId":"NCT07430202","phase":"PHASE1","title":"A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-05","conditions":"Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))","enrollment":27},{"nctId":"NCT04039607","phase":"PHASE3","title":"A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-09-30","conditions":"Hepatocellular Carcinoma","enrollment":732},{"nctId":"NCT04606316","phase":"PHASE1","title":"Surgical Nivolumab And Ipilimumab For Recurrent GBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Patrick Wen, MD","startDate":"2021-02-01","conditions":"Glioblastoma, GBM, Glioblastoma Multiforme","enrollment":63},{"nctId":"NCT05921760","phase":"PHASE1, PHASE2","title":"Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma","status":"TERMINATED","sponsor":"Servier Bio-Innovation LLC","startDate":"2023-10-23","conditions":"IDH1-mutant Cholangiocarcinoma","enrollment":7},{"nctId":"NCT05358938","phase":"EARLY_PHASE1","title":"Exercise to Boost Response to Checkpoint Blockade Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-06-21","conditions":"Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma","enrollment":22},{"nctId":"NCT00586391","phase":"PHASE1","title":"CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2009-02","conditions":"B Cell Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia","enrollment":14},{"nctId":"NCT05533697","phase":"PHASE1, PHASE2","title":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2022-09-01","conditions":"Advanced Solid Tumors","enrollment":361},{"nctId":"NCT04938232","phase":"PHASE2","title":"Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-06-04","conditions":"Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma","enrollment":13},{"nctId":"NCT05584670","phase":"PHASE1, PHASE2","title":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Sanofi","startDate":"2022-11-29","conditions":"Solid Tumor","enrollment":542},{"nctId":"NCT05779423","phase":"PHASE2","title":"Cryoablation+Ipilimumab+Nivolumab in Melanoma","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-09-23","conditions":"Metastatic Melanoma, Skin Cancer","enrollment":37},{"nctId":"NCT05428007","phase":"PHASE2","title":"Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-02-02","conditions":"Melanoma, Unresectable Melanoma","enrollment":105},{"nctId":"NCT03929029","phase":"PHASE1","title":"Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-11-11","conditions":"Cutaneous Melanoma","enrollment":11},{"nctId":"NCT07315035","phase":"PHASE2","title":"QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-01-01","conditions":"Gastric Cancer Stage III","enrollment":74},{"nctId":"NCT04933903","phase":"PHASE2","title":"BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab","status":"RECRUITING","sponsor":"Brown University","startDate":"2021-10-05","conditions":"Non Small Cell Lung Cancer","enrollment":25},{"nctId":"NCT01701674","phase":"NA","title":"Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-10-09","conditions":"Metastatic Melanoma","enrollment":13},{"nctId":"NCT07227012","phase":"PHASE1, PHASE2","title":"A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-01","conditions":"Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma","enrollment":138},{"nctId":"NCT03245892","phase":"PHASE1","title":"A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-08-04","conditions":"High Grade Serous Ovarian, Fallopian Tube, Primary Peritoneal Cancer","enrollment":27},{"nctId":"NCT06941857","phase":"PHASE2","title":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-09-04","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT04248569","phase":"PHASE1","title":"DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-04-20","conditions":"Fibrolamellar Hepatocellular Carcinoma (FLC)","enrollment":56},{"nctId":"NCT04117087","phase":"PHASE1","title":"Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-05-28","conditions":"Colorectal Cancer, Pancreatic Cancer","enrollment":27},{"nctId":"NCT05631899","phase":"PHASE1","title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-04-03","conditions":"Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V","enrollment":9},{"nctId":"NCT03233152","phase":"PHASE1, PHASE2","title":"A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2016-11-17","conditions":"Glioblastoma","enrollment":110},{"nctId":"NCT07155317","phase":"PHASE2","title":"Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-10-29","conditions":"Advanced Acral Melanoma, Advanced Cutaneous Melanoma, Advanced Mucosal Melanoma","enrollment":99},{"nctId":"NCT04665206","phase":"PHASE1, PHASE2","title":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Vivace Therapeutics, Inc","startDate":"2021-03-24","conditions":"Solid Tumor, Adult, Mesothelioma, NSCLC","enrollment":336},{"nctId":"NCT05220722","phase":"PHASE1, PHASE2","title":"Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors","status":"TERMINATED","sponsor":"TriSalus Life Sciences, Inc.","startDate":"2022-03-02","conditions":"Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma","enrollment":23},{"nctId":"NCT04935229","phase":"PHASE1","title":"Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma","status":"TERMINATED","sponsor":"TriSalus Life Sciences, Inc.","startDate":"2021-08-02","conditions":"Metastatic Uveal Melanoma in the Liver","enrollment":67},{"nctId":"NCT01592370","phase":"PHASE1, PHASE2","title":"An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-08-02","conditions":"Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma","enrollment":320},{"nctId":"NCT03949153","phase":"PHASE1, PHASE2","title":"Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2019-08-16","conditions":"Melanoma (Skin)","enrollment":19},{"nctId":"NCT05219435","phase":"PHASE2","title":"Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Oncology Genito-Urinary Group","startDate":"2022-07-06","conditions":"Urothelial Cancer","enrollment":66},{"nctId":"NCT05721846","phase":"PHASE1","title":"Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inna Chen, MD","startDate":"2023-05-03","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT06624644","phase":"PHASE2, PHASE3","title":"A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma","status":"RECRUITING","sponsor":"Linnaeus Therapeutics, Inc.","startDate":"2025-08-06","conditions":"Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma","enrollment":135},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT03646617","phase":"PHASE2","title":"Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2018-11-27","conditions":"Metastatic Melanoma","enrollment":54},{"nctId":"NCT04611126","phase":"PHASE1, PHASE2","title":"T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer","status":"TERMINATED","sponsor":"Inge Marie Svane","startDate":"2021-04-22","conditions":"Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer, Peritoneal Cancer","enrollment":6},{"nctId":"NCT01688492","phase":"PHASE1, PHASE2","title":"Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-09","conditions":"Prostate Cancer","enrollment":54},{"nctId":"NCT05444530","phase":"PHASE1","title":"A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-21","conditions":"Myeloproliferative Neoplasms","enrollment":14},{"nctId":"NCT05116202","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-02-02","conditions":"Melanoma","enrollment":110},{"nctId":"NCT04003649","phase":"PHASE1","title":"IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-12-02","conditions":"Recurrent Glioblastoma, Refractory Glioblastoma","enrollment":60},{"nctId":"NCT05310643","phase":"PHASE2","title":"Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC","status":"RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2022-05-05","conditions":"Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT03645928","phase":"PHASE2","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2019-05-07","conditions":"Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer","enrollment":245},{"nctId":"NCT03246958","phase":"PHASE2","title":"Nivolumab Plus Ipilimumab in Thyroid Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-10-03","conditions":"Thyroid Cancer","enrollment":53},{"nctId":"NCT03013491","phase":"PHASE1, PHASE2","title":"PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas","status":"TERMINATED","sponsor":"CytomX Therapeutics","startDate":"2017-01-19","conditions":"Solid Tumor, Lymphoma","enrollment":196},{"nctId":"NCT04730544","phase":"PHASE2","title":"Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2021-05-21","conditions":"Colorectal Cancer Metastatic, MSI-H Colorectal Cancer","enrollment":96},{"nctId":"NCT02743819","phase":"PHASE2","title":"Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2016-06-28","conditions":"Melanoma","enrollment":70},{"nctId":"NCT02397720","phase":"PHASE2","title":"Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-04-07","conditions":"Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":150},{"nctId":"NCT06031233","phase":"PHASE4","title":"Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie","status":"RECRUITING","sponsor":"Isala","startDate":"2023-09-01","conditions":"Oncology, Infusion Reaction","enrollment":679},{"nctId":"NCT05141721","phase":"PHASE2, PHASE3","title":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Project Corporation","startDate":"2022-02-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT03618641","phase":"PHASE2","title":"CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease","status":"COMPLETED","sponsor":"Diwakar Davar","startDate":"2018-08-08","conditions":"Melanoma, Lymph Node Cancer","enrollment":34},{"nctId":"NCT04472767","phase":"PHASE2","title":"Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2020-08-07","conditions":"Hepatocellular Carcinoma, HCC","enrollment":35},{"nctId":"NCT04141644","phase":"PHASE1","title":"Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2020-08-20","conditions":"Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)","enrollment":24},{"nctId":"NCT02196961","phase":"PHASE2","title":"Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation","status":"COMPLETED","sponsor":"Prof. Dr. med. Dirk Schadendorf","startDate":"2014-06","conditions":"Merkel Cell Carcinoma","enrollment":180},{"nctId":"NCT01355120","phase":"PHASE2","title":"THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease","status":"COMPLETED","sponsor":"Prof. Dr. med. Dirk Schadendorf","startDate":"2011-10","conditions":"Ocular Melanoma","enrollment":171},{"nctId":"NCT02523313","phase":"PHASE2","title":"Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED","status":"COMPLETED","sponsor":"Prof. Dr. med. Dirk Schadendorf","startDate":"2015-09-02","conditions":"Malignant Melanoma","enrollment":167},{"nctId":"NCT05012254","phase":"PHASE2","title":"Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación GECP","startDate":"2021-11-18","conditions":"Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer","enrollment":71},{"nctId":"NCT04239040","phase":"PHASE1","title":"GVAX Plus Checkpoint Blockade in Neuroblastoma","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-01-29","conditions":"Neuroblastoma, Pediatric Solid Tumor","enrollment":19},{"nctId":"NCT04247165","phase":"PHASE1, PHASE2","title":"Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.","status":"COMPLETED","sponsor":"Herlev Hospital","startDate":"2020-06-02","conditions":"Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer","enrollment":55},{"nctId":"NCT02278887","phase":"PHASE3","title":"Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2014-09-23","conditions":"Metastatic Melanoma","enrollment":168},{"nctId":"NCT03650894","phase":"PHASE2","title":"Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2019-04-03","conditions":"Breast Neoplasm Female, Breast Cancer, Breast Carcinoma","enrollment":30},{"nctId":"NCT06364631","phase":"PHASE3","title":"CARE1 Pragmatic Clinical Trial","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2024-04-12","conditions":"Metastatic Kidney Cancer, Metastatic Kidney Carcinoma","enrollment":1250},{"nctId":"NCT05456165","phase":"PHASE2","title":"Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer","status":"WITHDRAWN","sponsor":"Gritstone bio, Inc.","startDate":"2022-05-19","conditions":"Colonic Neoplasms, Colorectal Neoplasms","enrollment":""},{"nctId":"NCT03043599","phase":"PHASE1, PHASE2","title":"Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-02-13","conditions":"Small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer","enrollment":21},{"nctId":"NCT03153085","phase":"PHASE2","title":"A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma","status":"COMPLETED","sponsor":"Takara Bio Inc.","startDate":"2017-05-25","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":28},{"nctId":"NCT06519266","phase":"PHASE3","title":"PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2024-06-10","conditions":"Uveal Melanoma, Liver Metastases","enrollment":40},{"nctId":"NCT04855929","phase":"PHASE1","title":"A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.","status":"COMPLETED","sponsor":"Anaveon AG","startDate":"2021-05-25","conditions":"Advanced Solid Tumor, Adult Disease, Lung Cancer","enrollment":55},{"nctId":"NCT03296137","phase":"PHASE1, PHASE2","title":"Adoptive Cell Therapy Across Cancer Diagnoses","status":"COMPLETED","sponsor":"Inge Marie Svane","startDate":"2017-10-13","conditions":"Cancer","enrollment":25},{"nctId":"NCT02833233","phase":"NA","title":"A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-06","conditions":"Breast Cancer","enrollment":5},{"nctId":"NCT02027935","phase":"PHASE2","title":"CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-01-22","conditions":"Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7","enrollment":16},{"nctId":"NCT03647969","phase":"PHASE2","title":"Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2018-11-07","conditions":"Adenocarcinoma of the Stomach, GastroEsophageal Cancer","enrollment":262},{"nctId":"NCT03755739","phase":"PHASE2, PHASE3","title":"Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2018-11-01","conditions":"Hepatocarcinoma, Lung Cancer, Melanoma","enrollment":200},{"nctId":"NCT05187338","phase":"PHASE1, PHASE2","title":"Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2021-11-01","conditions":"Lung Cancer, Liver Cancer, Colorectal Cancer","enrollment":100},{"nctId":"NCT05116917","phase":"PHASE2","title":"Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.","status":"TERMINATED","sponsor":"Herlev Hospital","startDate":"2021-11-05","conditions":"Pancreatic Cancer","enrollment":19},{"nctId":"NCT01740297","phase":"PHASE1, PHASE2","title":"Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-02-07","conditions":"Melanoma","enrollment":217},{"nctId":"NCT02621515","phase":"PHASE2","title":"Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2016-08","conditions":"Melanoma, Brain Metastasis","enrollment":7},{"nctId":"NCT05074992","phase":"PHASE2","title":"A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma","status":"TERMINATED","sponsor":"University College, London","startDate":"2022-08-24","conditions":"Glioblastoma","enrollment":1},{"nctId":"NCT03711188","phase":"PHASE2","title":"A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma","status":"COMPLETED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2018-10-04","conditions":"Melanoma","enrollment":16},{"nctId":"NCT04124601","phase":"PHASE2","title":"Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer","status":"COMPLETED","sponsor":"Johannes Laengle, MD, PhD","startDate":"2020-06-01","conditions":"Rectal Cancer","enrollment":80},{"nctId":"NCT03126331","phase":"PHASE2","title":"Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2017-08-03","conditions":"Metastatic Renal Cell Carcinoma","enrollment":26},{"nctId":"NCT02723006","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2016-06-22","conditions":"Melanoma","enrollment":22},{"nctId":"NCT03728179","phase":"PHASE1","title":"RACIN in Patients With Advanced TIL-negative Solid Tumors","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2019-01-16","conditions":"Solid Tumor, Adult","enrollment":40},{"nctId":"NCT04840615","phase":"PHASE1","title":"Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-11","conditions":"Mesothelioma","enrollment":2},{"nctId":"NCT03068624","phase":"PHASE1","title":"Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma","status":"UNKNOWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-09-08","conditions":"Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma","enrollment":34},{"nctId":"NCT03850691","phase":"PHASE2","title":"Radiation and Combination Immunotherapy for Melanoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2019-05-28","conditions":"Metastatic Melanoma","enrollment":4},{"nctId":"NCT05041062","phase":"PHASE2","title":"A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2021-12-01","conditions":"Mesothelioma, Peritoneal Mesothelioma","enrollment":2},{"nctId":"NCT06159101","phase":"PHASE1","title":"A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2023-11-28","conditions":"Healthy Male Volunteers","enrollment":304},{"nctId":"NCT04894994","phase":"PHASE2","title":"FLX475 in Combination With Ipilimumab in Advanced Melanoma","status":"TERMINATED","sponsor":"RAPT Therapeutics, Inc.","startDate":"2021-09-03","conditions":"Advanced Melanoma","enrollment":6},{"nctId":"NCT02467361","phase":"PHASE1","title":"A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2015-08","conditions":"Cancer","enrollment":104},{"nctId":"NCT02488759","phase":"PHASE1, PHASE2","title":"An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-10-13","conditions":"Various Advanced Cancer","enrollment":578},{"nctId":"NCT03302234","phase":"PHASE3","title":"Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-12-14","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":568},{"nctId":"NCT02866383","phase":"PHASE2","title":"Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients","status":"COMPLETED","sponsor":"Herlev Hospital","startDate":"2016-11","conditions":"Metastatic Pancreatic Cancer, Metastatic Biliary Tract Cancer","enrollment":160},{"nctId":"NCT05631886","phase":"PHASE1","title":"Combination of CAR-DC Vaccine and ICIs in Malignant Tumors","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-07-04","conditions":"Solid Tumor, Adult, Lymphoma, EphA2 Overexpression","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["standard treatment"],"phase":"phase_3","status":"active","brandName":"Ipilimumab infusion","genericName":"Ipilimumab infusion","companyName":"The Netherlands Cancer Institute","companyId":"the-netherlands-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ipilimumab blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses. Used for Metastatic melanoma, Advanced melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}